

LTL-497 datasheet

Origin	Primary human ovarian cancer	Histopathology	Mucinous adenocarcinoma
Year of establishment	2012	Doubling time	4-5 days (subrenal capsule graft site)
Local invasion	Yes, limited	Metastasis	No

The LTL-497 (Fig. 1) was developed from a patient's primary ovarian cancer (Fig. 2, low grade mucinous adenocarcinoma). Morphologically it closely resembles the original patient's tumor. The LTL-497 grows well subcutaneously or at subrenal capsule graft site. When grafted at the subrenal capsule site, it shows limited local invasion into host kidney. No metastasis of LTL-497 in host is observed




Fig 1. H&E stained LTL-497 tissue sections.

Irregular glandular structures lined with stratified, mucin-containing or mucin-free tumor cells.




Fig 2. Patient's cancer tissue before grafting.

Genetic and epigenetic characteristics

Tumor line tissue (in tissue microarrays) for IHC and ISH is in place for screening potential targets upon request.

Applications

1. Pre-clinical evaluation of existing and potential anticancer drugs. Examination of drug efficacy on tumor growth, cell death (apoptosis, necrosis), tissue invasion, metastasis (in combination with metastatic tumor lines) and angiogenesis.
2. Discovery of potential therapeutic targets and/or biomarkers for drug sensitivity.
3. Study of mechanisms underlying tumor growth, progression and metastasis (in combination with metastatic tumor lines).

For more information, please contact us by email: LTL@bccrc.ca or phone: (604) 675 8013